Carisma Therapeutics Doses First Patient In Phase 1 Clinical Trial Of CT-0525, A Novel HER2-Targeting CAR-Monocyte
Portfolio Pulse from Benzinga Newsdesk
Carisma Therapeutics has dosed the first patient in a Phase 1 clinical trial of CT-0525, a novel HER2-targeting CAR-Monocyte. This is the first CAR-Monocyte to be evaluated in humans for solid tumors, with initial data expected by the end of 2024.
May 16, 2024 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Carisma Therapeutics has initiated a Phase 1 clinical trial for CT-0525, a novel HER2-targeting CAR-Monocyte, marking the first human evaluation of this therapy in solid tumors. Initial data is anticipated by the end of 2024.
The initiation of a Phase 1 clinical trial for a novel therapy is a significant milestone for Carisma Therapeutics. The potential for positive initial data by the end of 2024 could drive investor interest and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100